ABSTRACT Background: Total parenteral nutrition (TPN) is an invasive and advanced rescue feeding technique that has acceptable short-term survival although at costs of substantial risks. Survival after the clinical use of TPN .6 mo is unknown. Objective: We determined long-term survival after clinical TPN use in a consecutive cohort who were attending an academic hospital. Design: The study included a prospective cohort with a retrospective analysis of all 537 consecutive episodes of TPN in 437 patients between January 2010 and April 2012. Follow-up was until October 2013 with a total follow-up of 608 patient-years. Survival was analyzed by using Kaplan-Meier and Cox regression. Results: Survival was 58% in 437 patients with a first-time use of TPN at an average of 1.5 y after the initiation of TPN. The mortality rate was 30 deaths/100 patient-years. Older age, admission at an intensive care unit or a nonsurgical department, lower body mass index, and an underlying malignancy were positively associated with mortality. Conclusion: TPN use, if correctly indicated, is a clinical sign of intestinal failure and a surrogate marker for markedly increased risk of mortality even .1.5 y after TPN use. This trial was registered at clinicaltrials.gov as NCT02189993 with protocol identification name TPN-01.
INTRODUCTION
Total parenteral nutrition (TPN) 4 is the last resort to feed patients with clinically important intestinal failure who cannot be sufficiently fed via the enteral route. The application of TPN has developed since the 1970s. TPN is currently widely used in intensive care units (ICUs), surgical and nonsurgical wards, and even in a home setting. By means of TPN, nutrients are delivered when this supply is impossible, contraindicated, or inadequate via the usual enteral route. It is well known that malnutrition is associated with a poor outcome in almost any severe disease (1) . Therefore, TPN is thought to benefit patient outcomes when there is a just indication for the initiation of TPN (2) .
Patients with upper gastrointestinal cancer might benefit in terms of a lower number of major complications. This absolute risk difference implied that one such complication could be avoided for every 5.5 patients treated (95% CI: 3.2, 16.7 patients) (2) . However, these results have come from low-quality trials, which could have overestimated the actual beneficial effect (3) . In contrast, 2 meta-analyses of randomized controlled trials did not show that the use of TPN compared with no (enteral) feeding was associated with a lower mortality rate (3, 4) . Specifically, in patients with protein-energy malnutrition, TPN seemed beneficial in terms of lower risk of mortality or infections compared with that for standard care with enteral feeding. In particular, in well-nourished patients, the benefit of TPN is doubted (4) .
Conceptually, it has been argued that an experiment to prove the benefit of TPN cannot be performed because TPN should be started in individuals who are thought to truly benefit, namely those with true intestinal failure. Other authors have argued that it is unethical to initiate an unproven and potentially dangerous therapy in patients (3) .
The clinical therapeutic benefit of TPN has not been fully established. Therefore, it is important to evaluate TPN because TPN is associated with morbidity and even mortality. Complications associated with TPN use in the short term include water and electrolyte disorders, (eg, the refeeding syndrome) and complications related to the insertion and care of a central venous catheter, including pneumothorax or infections (5) . As mentioned before, there is also a substantial mortality in patients who use TPN, although the exact relation with TPN remains to be clarified. A prospective study from England reported 20% mortality within 28 d (6). Short-term mortality rates have been reported between 2-43% in (randomized) clinical trials. However, results from these clinical trials are difficult to extrapolate to the actual, regular clinical use of TPN because of the strictly defined and specific populations in these trials (7) (8) (9) (10) .
Follow-up in most studies has been limited to 4-6 mo, and less is known about long-term survival after TPN use. Because of the relatively high short-term mortality, an investigation of the long-term survival is of critical clinical importance to assess the clinical value of this invasive and advanced feeding technique. Therefore, we analyzed the long-term survival in clinical TPN use in a cohort of consecutive TPN-using patients in an academic hospital setting.
SUBJECTS AND METHODS
The VU University Medical Center is a tertiary referral, academic hospital. For this study, all consecutive patients who were using TPN from 1 January 2010 to 30 April 2012 were analyzed with the exclusion of patients from the Pediatric and Haematological Departments because of different department-specific TPN protocols. In total, 437 patients with 537 episodes of TPN were included in this study. TPN was initiated by the treating physician usually after consultation with the Nutrition Support Team.
Nutrition Support Team
Patients who initiated TPN were monitored by a dedicated Nutrition Support Team consisting of dietitians (SMtD and SDWdG), a TPN nurse (WA), and a gastroenterologist with a specific nutritional background (AAvB). If necessary, a pharmacist or ICU physician was consulted. All patients who were using TPN were discussed in a weekly meeting attended by the Nutrition Support Team. Details of all patients who were receiving TPN were prospectively recorded by the Nutrition Support Team.
Indications and TPN protocol
TPN was started according to the local protocol when there was intestinal failure present for 5 d or clinically likely to persist .5 d. Intestinal failure was defined as an insufficient oral or enteral diet in terms of energy or protein demands. Furthermore, TPN was considered before an operation in the case of malnourishment according to Dutch guidelines of preoperative nourishment (11) . However, treating physicians could initiate TPN at their own discretion. Indications for the start TPN were classified into the following 4 categories: 1) enteral feeding was not possible, 2) enteral feeding was contraindicated, 3) enteral feeding was inadequate, and 4) an inadequate use of TPN (as defined by the hospital protocol and judged by the Nutrition Support Team). The discontinuation of TPN was decided by the treating physician, usually after consultation with the Nutrition Support Team. A suspicion of a central venous catheter infection was judged by the treating physician or the Nutrition Support Team. Tip cultures were retrieved from the hospital database. Blood cultures were retrieved from the hospital database. Central line-associated bloodstream infections (CABSI) were determined according to CDC criteria (a positive blood culture with a central catheter in place for $48 h). We prospectively recorded to what department patients were admitted and grouped departments in nonsurgical (including ICU, Internal Medicine, Oncology, and other) and surgical (Gastrointestinal surgery; ICU; Traumatology; Vascular surgery; Gynecology; Ear, Nose, and Throat; and other). Patients were also grouped whether or not they were admitted to the ICU (which could be by surgical and nonsurgical specialties).
Data collection
With all patient records addressed, we recorded the duration of hospital admission and overall survival. Follow-up was retrieved up to October 2013. The duration of follow-up was defined as the interval in years between the date of starting TPN and follow-up defined as the date of mortality or last known date of contact. The outcome of TPN therapy was analyzed by retrieving patients' files according to hospital and national regulations regarding investigational conduct.
Statistical analysis
Analyses were performed with SPSS version 19.0 software (IBM SPSS Inc). Parametric variables are given as means 6 SDs, and nonparametric variables are given as medians (IQRs). The normal distribution was tested by using the KolmogorovSmirnov test. Differences in parametric variables were tested by using a t test, and differences between dichotomic variables were tested by using a chi-square test. A survival analysis was performed in the following predefined manner. Initially, a univariate analysis was performed with a log-rank test and KaplanMeier curves with the following variables: sex, BMI (in kg/m 2 ) (in 2 groups: BMI ,25 and $25), malignancy (present or not present), surgical or nonsurgical departments, ICU admission, indication for TPN [1) enteral feeding was not possible, 2) enteral feeding was contraindicated, 3) enteral feeding was inadequate, or 4) an inadequate use of TPN], and TPN use ,5 d. This latter analysis was performed only in patients with survival $5 d and in all patients with survival $30 d. A Cox-regression analysis was performed with the previously named variables and age. In the Cox-regression analysis, age and BMI were used as continuous variables.
Ethics and study registration
This research was performed in accordance with the ethical standards of the responsible institutional committee on human experimentation (Medical Ethical Commission, VU University Medical Center). This trial was registered at clinicaltrials.gov as NCT02189993 with protocol identification name TPN-01.
RESULTS
We analyzed 437 patients with 537 episodes of TPN. The average age was 60 6 16 y when TPN was started for the first time. In 240 cases, TPN was started in men (55%). Mean BMI was 24.0 6 4.8. The median duration of TPN was 7 d (4-13 d). Most patients were admitted by surgical specialties. Forty-three percent of patients required a hospital admission because a malignancy as an underlying disease. In 70% of patients, enteral feeding was not possible mainly because of an ileus. Inadequate enteral feeding was the second most-important indication. Only 20 patients (5%) did not have an adequate indication for TPN. Additional details are shown in Table 1 .
Patient details are shown in Table 2 according to nonsurgical and surgical departments or an ICU admission. Patients admitted to nonsurgical departments were younger and had a longer duration of admittance than did patients admitted to surgical departments. Moreover, there were more ICU admissions in the nonsurgical group. Durations of the use of TPN and malignancy LONG-TERM SURVIVAL AFTER TPN as an underlying reason for admittance were similar between nonsurgical and surgical groups. In the ICU group, more than one-half of patients received TPN ,5 d.
A total 537 episodes of TPN were recorded in 370 patients who received TPN only once during an admission, 50 patients received TPN on 2 separate admissions, 11 patients had 3 admissions that required TPN, and 8 patients had .3 admissions that required TPN.
For the 437 patients with their first episode of TPN, the median follow-up was 1.5 y (0.3-2.2 y) with a total follow-up of 608 patient-years (Table 1) . We registered 48 complications (11%) including 11 cases of central venous catheter dysfunction and 37 cases (8.5%) of a suspicion of a central venous catheter infection ( Table 1) . Central venous catheter infections were corroborated in 15 subjects (3.4%) by a positive blood culture. The event rate for CABSI was 3.5 events/1000 d central line use. In the 100 episodes of TPN after the first clinical use of TPN, we registered an additional 8 complications (8%).
The overall mortality was 42% (n = 183) in 1.5 y (0.3-2.2 y) after the start of the first episode of TPN. The overall mortality rate was 30 deaths/100 patient-years. Mortality within 30 d after the initiation of TPN was 13% (n = 57). Mortality in relation to the number of admissions with TPN is shown in Table 3 . The overall mortality increased to 60% in patients who required TPN during more than one admission. Patients who required TPN during an ICU admission had an overall mortality of 62% (82 of 131 patients; mortality rate: 66 deaths/ 100 patient-years), whereas the overall mortality was 60% in patients admitted by a nonsurgical specialty (64 of 107 patients; mortality rate: 50 deaths/100 patient-years) compared with 36% in patients admitted by surgical specialty (119 of 330 patients; mortality rate: 26 deaths/100 patient-years). In patients with a malignancy, mortality was 50% (93 of 187 patients) compared with 36% in patients without a malignancy (90 of 250 patients).
A univariate survival analysis was performed by using Kaplan-Meier curves. As shown in Figure 1 , ICU admission, admission to nonsurgical department, BMI considered above normal ($25), and the presence of a malignancy were associated with a poorer survival. Sex (figure not shown; log-rank test: P = 0.8) and the indication for TPN (figure not shown; log-rank test: P = 0.6) were not univariately related to survival. Patients without an adequate indication for TPN had a comparable mortality as that for those with an adequate indication [8 of 20 patients (40%) compared with 175 of 417 patients (42%); log-rank test P = 0.8]. The analysis with BMI indicated that patients with BMI $25 had improved survival (65%) compared with that for patients with BMI ,25 (survival of 54%). Mortality was similar in patients with TPN #5 or .5 d (log-rank test: 0.2) in the 365 patients with follow-up $30 d. This analysis was similar in the 408 patients with a survival $5 d (log-rank test: P = 0.3)
A multivariate Cox regression analysis was performed for the analysis of mortality for the 437 patients who started TPN for the first time. Older age, intensive care admission, lower BMI, nonsurgical department admission, and an underlying malignancy were significantly associated with greater risk of mortality ( Table 4) . There was no relation between the indication for TPN and mortality (P = 0.8). The strength, or b, of the association was similar between mortality and intensive care admission and mortality and nonsurgical department admission. Furthermore, mortality was not different between nonsurgical patients admitted to a regular ward and nonsurgical patients admitted to the ICU (log-rank test: P = 0.2).
DISCUSSION
The survival rate was 58% in 437 patients with a first-time use of TPN at an average of 1.5 y after the initiation of TPN. Older age, admission at an ICU, admission to a nonsurgical department, lower BMI, and an underlying malignancy were positively associated with mortality. In our study, there were 56 TPN-related complications in 537 episodes of TPN use, mainly during non-ICU admissions.
To our knowledge, mortality after TPN use has only been reported up to a maximum of 6 mo and in specific patient categories (6) (7) (8) (9) (10) . Mortality within the first 6 mo has been reported to be between 2% and 43%. For comparison, the mortality rate of 30 deaths/100 patient-years after clinical TPN use in our study was higher than that in patients in need of dialysis because of renal failure (mortality rate: 16 deaths/100 patient-years (12) or heart failure [mortality rate: 12 deaths/100 patient-years (13)]. Patients receiving dialysis who have heart failure and are admitted to an ICU have dedicated medical treatment by numerous medical providers. Studies that investigated the role of a nutrition support team indicated a reduced inappropriate TPN use, less catheter-related sepsis, and even improved survival (14) (15) (16) (17) (18) (19) . These outcomes were already shown in the 1980s (18, 19) . The improved efficacy of TPN use resulted in reduced costs in most studies (14) (15) (16) .
Admission to a nonsurgical department was associated with a higher mortality rate than that for admission to a surgical department (50 compared with 26 deaths/100 patient-years). We could not relate this higher mortality rate to age or an underlying malignancy; nonsurgical patients were younger than surgical patients. However, compared with surgical patient, nonsurgical patients had almost twice the number of ICU admissions. Other possibilities for a higher mortality in nonsurgical patients could have been differences in patient selection of those receiving TPN or differences in physicians' discretion between nonsurgical and surgical departments. It is possible that patients with reversible intestinal failure, such as an ileus amended by a surgical intervention, were predominantly admitted by surgical specialties. 
Nonsurgical (n = 107) Surgical (n = 330) P-difference 2 Non-ICU (n = 306) ICU (n = 131) P-difference Besides mortality, our study also highlights the considerable complication rate of 11%. Complications were mainly due to the suspicion of a central line infection. In our study, the CABSI rate was 1.1/1000 catheter days in the ICU and 4.1 in non-ICU wards. These rates are comparable to data in the literature. In 55 ICUs, the median CABSI was 2.7/1000 catheter days, with an IQR of 0.6-4.8 (20) . In 4 non-ICU medical wards, CABSI had a range between 4.3 and 8.0/1000 catheter days (21) .
Another finding was that higher BMI was associated with a better survival. We did not show that a very low BMI was associated with a poor survival. This was also seen in patients with peritoneal carcinomatosis (22) . Perhaps patients with higher BMI have greater reserves, but unfortunately, we did not have reliable information on nutritional status (and fat-free mass in particular) to further investigate this relation.
Our study had several limitations, most notably the retrospective character of assessing the long-term outcome. However, all patients had at least follow-up during admission, and the greatest majority of patients were seen at our outpatient clinics. Also, the retrospective follow-up could only underestimate the long-term mortality. We were not informed of comorbidity or underlying disease that required the admission of the patient. Finally, not all patients had an appropriate indication for TPN, and 37% of patients received ,5 d TPN. However, the fact that some patients had an inappropriate indication for TPN reflects actual TPN use, and inappropriate indications have also been often noted in other studies of actual TPN use (6, 23) . Furthermore, an inappropriate use of TPN was not associated with excess mortality. A strength of our study was the long follow-up of an average of 1.5 y and 608 patient-years of follow-up.
In conclusion, our study underlines that complete intestinal failure, for which the clinical use of TPN is necessary, is associated with a remarkably high, long-term mortality rate of 42%. This outcome was particularly observed in nonsurgical patients. TPN should not be regarded as a simple dietary measure but as a high complex medical intervention. TPN requires an appropriate indication, a dedicated, knowledgably team, and thorough nutritional and clinical follow-up. TPN use is a clinical sign of intestinal failure and a surrogate marker for markedly increased risk of mortality.
The authors' responsibilities were as follows-LHO and AAvB: designed the research protocol and had primary responsibility for the final content of the manuscript; LHO, SMtD, SDWdG, and WA: conducted the research; SMtD, SDWdG, and WA: provided essential materials; LHO: performed the statistical analysis; and LHO, SMtD, SDWdG, WA, and AAvB: wrote drafts of the manuscript. None of the authors had a conflict of interest. 
